Grant ID DP150093
Awarded On November 19, 2014
Title Targeting an Elusive Foe: Development of K-Ras Inhibitors
Program Academic Research
Award Mechanism Bridging the Gap: Early Translational Research Awards
Institution/Organization The University of Texas Health Science Center at Houston
Principal Investigator/Program Director Alemayehu Gorfe
Cancer Sites Bladder, Colorectal, Lung and Bronchus, Pancreas, Stomach
Contracted Amount $1,969,826
Lay Summary

The United States National Cancer Institute estimates that there will be close to 1.7 million new cancer cases and 585,720 cancer-related deaths in 2014. Activating mutations of a key enzyme in humans, called K-Ras, are known to occur in about 25% of all human cancers. Combining these two statistics, we estimate that about 400,000 US citizens will be affected by one or another form of K-Ras-related cancers this year alone.

Currently, there are no drugs that can directly act on mutated K-Ras to stop its cancer-causing activities. As a result, K-Ras-related cancers remain untreatable, including some of the deadliest such as pancreatic cancer. In fact, the prognosis of K-Ras-associated cancers...

Read More